Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 9/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.72 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.72 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.72 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.72 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.72 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.72 |
| ▸ | TTR | P02766 | 2/20 | 0.61 |
| ▸ | P4HB | P07237 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | UNG | P13051 | 1/20 | 0.56 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.56 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13860524 | 0.88 | TTR (0.63) | HDAC3HDAC1HDAC2HDAC8HDAC4 | |
| SCHEMBL13860523 | 0.88 | TTR (0.63) | HDAC3HDAC1HDAC2HDAC8HDAC4 | |
| SCHEMBL675746 | 0.87 | HDAC1 (1.00) | HDAC3HDAC1HDAC2HDAC8HDAC4 | |
| SCHEMBL29392550 | 0.87 | HDAC1 (1.00) | HDAC3HDAC1HDAC2HDAC8HDAC4 | |
| SCHEMBL29354058 | 0.87 | HDAC1 (1.00) | HDAC3HDAC1HDAC2HDAC8HDAC4 | |
| SCHEMBL675747 | 0.87 | HDAC1 (1.00) | HDAC3HDAC1HDAC2HDAC8HDAC4 | |
| SCHEMBL11974382 | 0.85 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC8HDAC4 | |
| SCHEMBL25049810 | 0.85 | HDAC1 (0.74) | HDAC3HDAC1HDAC2HDAC8HDAC4 | |
| SCHEMBL6369565 | 0.84 | HDAC1 (1.00) | HDAC3HDAC1HDAC2HDAC8HDAC4 | |
| SCHEMBL11974531 | 0.83 | HDAC3 (0.80) | HDAC3HDAC1HDAC2HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763670-B1 | REACTIVATION OF HIV-1 GENE EXPRESSION TO TREAT PERSISTENT HIV INFECTION | UNIV BRUXELLES (BE) | 2018-12-05 | — | — | EP | claimed |
| US-9943536-B2 | Reactivation of HIV-1 gene expression to treat persistent HIV infection | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2018-04-17 | — | — | US | claimed |
| US-20150023907-A1 | REACTIVATION OF HIV-1 GENE EXPRESSION TO TREAT PERSISTENT HIV INFECTION | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2015-01-22 | — | — | US | claimed |
| EP-2763670-A1 | REACTIVATION OF HIV-1 GENE EXPRESSION TO TREAT PERSISTENT HIV INFECTION | Université Libre de Bruxelles (BE) | 2014-08-13 | — | — | EP | claimed |
| WO-2013050422-A1 | REACTIVATION OF HIV-1 GENE EXPRESSION TO TREAT PERSISTENT HIV INFECTION | Université Libre de Bruxelles (BE) | 2013-04-11 | — | — | WO | claimed |
| US-20240226039-A1 | IMMUNE CHECKPOINT INHIBITOR AND HDAC INHIBITOR COMBINATION THERAPY STRATEGY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2023241799-A1 | FLAVANOLS FOR USE IN THE TREATMENT OF RETROVIRAL INFECTIONS | Université Libre de Bruxelles (BE) | 2023-12-21 | — | — | WO | disclosed |
| US-10449245-B2 | Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent | BIONOR IMMUNO AS (NO) | 2019-10-22 | — | — | US | disclosed |
| US-10335482-B2 | Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer | BIONOR IMMUNO AS (NO) | 2019-07-02 | — | — | US | disclosed |
| US-20190183870-A1 | COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2019-06-20 | — | — | US | disclosed |
| EP-2763670-B1 | REACTIVATION OF HIV-1 GENE EXPRESSION TO TREAT PERSISTENT HIV INFECTION | UNIV BRUXELLES (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-10143737-B2 | Method for the vaccination against HIV | BIONOR PHARMA ASA (NO) | 2018-12-04 | — | — | US | disclosed |
| US-20040087631-A1 | Methods of treating cancer with HDAC inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-05-06 | — | — | US | disclosed |
| US-20040072735-A1 | Methods of inducing terminal differentiation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
| US-20040018968-A1 | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| US-20030235588-A1 | Method of treating TRX mediated diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-25 | — | — | US | disclosed |
| WO-2003088954-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003075839-A2 | METHODS OF INDUCING TERMINAL DIFFERENTIATION | ATON PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003070188-A2 | METHOD OF TREATING TRX MEDIATED DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003032921-A2 | TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER OF THE BRAIN | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10335482-B2 | Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer | CD4, C5, C9 | HDAC3 4599/4885HDAC1 4481/4885HDAC2 4693/4885 |
| US-20030235588-A1 | Method of treating TRX mediated diseases | TXN, TXNRD3, TXNRD2 | HDAC3 16/4885HDAC1 8/4885HDAC2 5/4885 |
| US-20040087631-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC1, HDAC4 | HDAC3 4/4885HDAC1 2/4885HDAC2 6/4885 |
| US-10143737-B2 | Method for the vaccination against HIV | CD4, KLK3, CCR5 | HDAC3 3047/4885HDAC1 2871/4885HDAC2 4060/4885 |
| US-20150023907-A1 | REACTIVATION OF HIV-1 GENE EXPRESSION TO TREAT PERSISTENT HIV INFECTION | NFATC1, CD69, STING1 | HDAC3 70/4885HDAC1 7/4885HDAC2 68/4885 |
| US-20040072735-A1 | Methods of inducing terminal differentiation | HDAC3, HDAC1, HDAC5 | HDAC3 1/4885HDAC1 2/4885HDAC2 7/4885 |
| US-20040018968-A1 | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer | HDAC1, HDAC5, HDAC2 | HDAC3 5/4885HDAC1 1/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.